[To learn English]
Brazil's health regulator Anvisa said on Tuesday it had approved EMS's Ozivy, the country's first semaglutide-based injector pen, as the drugmaker looks to expand into a higher-end segment of the global pharmaceutical industry.
The drug uses the same active ingredient as Novo Nordisk's diabetes and weight-loss drug Ozempic, whose patent expired in Brazil in March.
Drug to be produced at EMS plant in Sao Paulo state with capacity for up to 40 million pens per year.
巴西卫生监管机构Anvisa周二批准了EMS公司的Ozivy，这是该国首款基于司美格鲁肽的注射笔，这家制药商正寻求拓展至全球制药行业的高端领域。
该药物使用的活性成分与诺和诺德的糖尿病和减肥药Ozempic相同，后者在巴西的专利已于三月份到期。
该药将在EMS位于圣保罗州的工厂生产，年产能高达4000万支注射笔。
LearnEnglish Leave a remark